
Bicara Therapeutics fell 35.2% from $15.05 to $9.75, behind the S&P 500's +11.2%. Its worst day was Oct 28 (−44.2%), and its low came Nov 2 at $7.93.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.68 beat the $-0.68 estimate on $0.00 revenue.
+3.6% · S&P 500 −0.3%
EPS of $-0.93 missed the $-0.65 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
+1.5% · S&P 500 +0.2%
Bicara Therapeutics closed at its highest level of the year, 102.0% above where the year started.
+4.0% · S&P 500 −0.5%
EPS of $-0.82 missed the $-0.81 estimate on $0.00 revenue.
−14.3% · S&P 500 −0.3%
Bicara Therapeutics shares fell 44.2%, while the S&P 500 rose 0.3%.
−44.2%, the year's worst day, on 15M shares, the year's heaviest volume · S&P 500 +0.3%
EPS of $-1.04 missed the $-0.86 estimate on $0.00 revenue.
+15.4%, the year's best day · S&P 500 +2.4%
Where it ended: a close of $9.75 on Nov 16, 2026.
Nothing in the past 12 months.
All BCAX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BCAX and SPY from Benzinga historical bars. Not investment advice.